Recent Therapeutic Advances in the Management of Metastatic Bladder Cancer: Managed Care Perspectives on Immunotherapy in the First Line Setting is a three-part webinar series

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Bladder Cancer

These are archives of live webinars held between January 27, 2021 to February 3, 2021
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from March 1, 2021 to March 1, 2023


This series is supported by an educational grant from
Pfizer


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there will be 80,470 new cases of bladder cancer and 17,670 deaths in the United States in 2020. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer, which led to the introduction of immune checkpoint inhibitors. However, when those options fail, options are sparse to manage this difficult disease. Fortunately for patients with metastatic bladder cancer, new agents, including antibody-drug conjugates, have recently emerged for patients who have failed on immunotherapy and chemotherapy. It is for this reason that medical directors, oncologists, practicing physicians, nurse case managers and other healthcare professionals must be educated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the metastatic bladder cancer patient population.

While immunotherapy has revolutionized care for metastatic bladder cancer, it doesn't work for everyone. Patients who progress with or fail immunotherapy will need subsequent therapy, and there is limited data to guide treatment selection. New data from late-stage clinical trials introduce emerging targeted agents with great promise in improving outcomes for these patients. As these options have recently become available and shown the ability to improve outcomes in patients with this difficult to treat disease, it is imperative that physician medical directors, oncologists, practicing physicians, nurse case managers and other healthcare professionals are brought up to date regarding these novel treatments, so that they can properly approve and select therapy based on individual patient characteristics for improved clinical and economic outcomes.


A Closer Look at Immunotherapy in the First Line Management of Metastatic Bladder Cancer: Maintenance Options for Improved Clinical and Economic Outcomes

  1. Identify current unmet clinical and economic needs in the management of metastatic bladder cancer and evidence-based recommendations for the care of patients with these tumors
  2. Examine recent clinical data on the safety and efficacy of immune checkpoint inhibitors in the management of metastatic bladder cancer in the first line setting
  3. Assess recent evidence on the role of maintenance immunotherapy in the first line management of metastatic bladder cancer
  4. Explore the role of sequential therapy and the differences between upfront treatment and sequencing strategies with immune checkpoint inhibitors in metastatic bladder cancer
  5. Identify patients with metastatic bladder cancer who would potentially benefit from immunotherapies, in first line maintenance settings or beyond
       Physician, Nursing and CMCN credits valid to March 1, 2023

Comparative Effectiveness and Payer-Provider Coordination in Metastatic Bladder Cancer: What Managed Care Needs to Know About Recent Advances in First Line Immunotherapy?

  1. Identify current unmet economic needs in the management of metastatic bladder cancer and evidence-based recommendations for the care of patients with these tumors
  2. Review the role of immune checkpoint inhibitors in the management of metastatic bladder cancer in the first line setting
  3. Describe approaches currently utilized by third party payers to manage costs associated with the care of patients with metastatic bladder cancer
  4. Discuss the managed care considerations of first line immunotherapy by exploring where these agents fit in the evolving metastatic bladder cancer management paradigm
  5. Transform therapeutic advances and resource utilization data on emerging therapies in metastatic bladder cancer into informed health plan decisions and formulary discussions
       Physician, Nursing and CMCN credits valid to March 1, 2023

Improving Patient Adherence and Quality of Life in Metastatic Bladder Cancer: Strategies for Managing Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

  1. Examine challenges to patient adherence, administration and quality of life in the management of metastatic bladder cancer
  2. Discuss strategies to implement immune checkpoint inhibitors into the treatment paradigm, especially as it relates to patient adherence and quality of life
  3. Review strategies to prevent, anticipate, and manage immune-related adverse events (irAEs) in patients with metastatic bladder cancer
  4. Explore the role of first-line immunotherapy maintenance in the management of metastatic bladder cancer
       Physician, Nursing and CMCN credits valid to March 1, 2023